Freshfields advises Bio-Rad in relation with its binding offer to acquire Stilla Technologies

Global law firm Freshfields advised Bio-Rad, a US leader in life science research and clinical diagnostics products, on its binding offer to acquire the all equity interest in French Digital PCR Developer Stilla Technologies. The acquisition remains subject to consultation with relevant employee representatives and other closing conditions, and is expected to close by the end of the third quarter of 2025.

Once closed, the acquisition will support the development of Bio-Rad’s strategy to further expand its business into applied research and clinical diagnostics.

The Freshfields team was led by Guillemette Burgala, partner, with Jules Troubat, senior associate and Lucas Cloarec, associate, on the corporate aspects. Guilhem Bremond, partner, Soraya Ameline, Raphael Latorre, Samvel Der Arsenian, and Marwan Hammache, associates, advised on the restructuring and financing aspects. Meghan Rissmiller, Charlotte Colin-Dubuisson and Jérôme Philippe, partners, Sara Gil Garcia, counsel and Anaïs Jennepin, associate, advised on the foreign investment and merger control aspects. Christel Cacioppo, partner, Matthias Triolle and Antoine Le Stang, associates, advised on social aspects. Vincent Daniel-Mayeur, partner and Julia Videau, senior associate, advised on tax aspects. David Brooks, partner, and Ben Cohen, senior associate, advised on the intellectual property aspects.